Biotech News

Cingulate Announces U.S. Patent Issuance for CTx-2103, Further Validating PTR™ Technology Platform

Cingulate Inc. (CING)Cingulate Inc.Company update

New Patent Strengthens Cingulate’s Intellectual Property Portfolio While Company Maintains Focus on Advancing Lead ADHD Candidate CTx-1301 New Patent Strengthens Cingulate’s Intellectual Property Portfolio While Company Maintains Focus on Advancing Lead ADHD Candidate CTx-1301

Related news

Cingulate Inc.

Precision Timed Release Platform Cingulate develops next-generation medicines using its Precision Timed Release platform. The technology uses multi-core tablets to deliver several precisely timed drug releases during the day, with the goal of extending therapeutic coverage and improving adherence. CTx-1301 ADHD Candidate CTx-1301 is a...

Recent company news

Stock data

Close
5.26 USD
Market cap
54.28M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States